What does Arch Pharmalabs Limited do?

Arch Pharmalabs Limited is a Mumbai-based API (Active Pharmaceutical Ingredient) manufacturer incorporated in 1993. The company owns and manages 9 multipurpose manufacturing facilities and has technology partnerships with Codexis (USA), Orochem Technologies (USA), and DSM (Netherlands) for advanced pharmaceutical chemistry.

What is the ISIN of Arch Pharmalabs Limited?

The ISIN for Arch Pharmalabs Limited is INE072H01012.

Is Arch Pharmalabs Limited listed on any stock exchange?

Arch Pharmalabs Limited is currently classified as an unlisted company. Despite having a confirmed ISIN (INE072H01012), shares trade on unlisted grey market platforms at approximately ₹90.1 per share.

What manufacturing infrastructure does Arch Pharmalabs have?

Arch Pharmalabs operates 9 multipurpose manufacturing facilities, allowing it to produce a diverse range of API products across different therapeutic categories with operational flexibility.

What technology partnerships does Arch Pharmalabs have?

Arch Pharmalabs has technology tie-ups with Codexis (USA) for biocatalytic API manufacturing, Orochem Technologies (USA) for advanced separation and purification, and DSM (Netherlands) for specialty pharmaceutical chemicals.

Is Arch Pharmalabs planning an IPO?

No official IPO announcement has been confirmed for Arch Pharmalabs Limited. The company remains unlisted with shares available through grey market intermediaries.

How do I buy Arch Pharmalabs unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for Arch Pharmalabs?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell Arch Pharmalabs shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

Arch Pharmalabs Unlisted Share Price | Buy Arch Pharmalabs Pre-IPO Shares — wisefolio

Investment Thesis

Arch Pharmalabs Limited is a large-scale API manufacturer (Rs.1,340 Cr revenue) that was acquired by Neuland Laboratories in December 2017. The standalone entity is delisted, with equity value reflected through Neuland Laboratories (NSE: NEULANDLAB).

Pros

Revenue of Rs.1,340 Cr (FY23) — large-scale API/custom synthesis pharma manufacturer.
Backed by Mitsui (Japan) with 30% stake — strong institutional validation and global access.
Acquired by Neuland Laboratories in Dec 2017 — now part of a publicly listed API powerhouse.
Specializes in small molecule process chemistry, custom synthesis, and full life-cycle API manufacturing for global pharma.

Cons

Delisted — no longer an independently tradeable entity; absorbed into Neuland Laboratories.
Equity shareholders of the original Arch Pharmalabs entity have no secondary market.
API manufacturing is subject to stringent global regulatory oversight (USFDA, EMA); GMP compliance is perpetual cost.
Post-acquisition, operations and financials are consolidated into Neuland — standalone Arch Pharmalabs visibility is zero.

Business Segments

API Manufacturing

Manufacture of Active Pharmaceutical Ingredients (APIs) and drug intermediates; full life-cycle support from process chemistry to commercial production.

Custom Synthesis & Contract Manufacturing

Custom synthesis services for global pharma companies; CDMO-style contract manufacturing for small molecules.

Revenue Model

Arch Pharmalabs Limited generates revenue through the manufacture and sale of active pharmaceutical ingredients (APIs) to domestic and international formulation companies. Additional revenue streams include contract manufacturing services and custom synthesis projects undertaken through its technology partnerships with Codexis, Orochem Technologies, and DSM. The company's 9 multipurpose facilities allow rapid product switching to capture market demand across therapeutic areas.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds12

Growth Plans

Global pharmaceutical supply chain diversification (China+1) benefiting Indian API producers

India PLI scheme for pharmaceuticals supporting API manufacturers

Potential IPO listing to raise capital and improve investor visibility

Growing demand for complex APIs and CDMO services globally

Industry Tailwinds

Recent Developments

India API sector benefits from China+1 strategy

Global pharmaceutical companies are diversifying API sourcing away from China, benefiting established Indian API manufacturers like Arch Pharmalabs with global technology partnerships.

2024-01

Comparable Companies

CompanyTypeTickerMkt Cap

Divi's LaboratoriesPE: ~55xxListedDIVISLAB~1,00,000 Cr

Laurus LabsPE: ~35xxListedLAURUSLABS~22,000 Cr

Solara Active Pharma SciencesListedSOLARA~1,500 Cr

Aarti PharmalabsPE: ~25xxListed

Frequently Asked Questions

About Arch Pharmalabs

Arch Pharmalabs Limited is a Mumbai-based Active Pharmaceutical Ingredients (API) manufacturer incorporated in 1993. The company was once a significant player in India's bulk drug manufacturing sector, producing APIs for cardiovascular, anti-infective, anti-diabetic, and other therapeutic categories. At its peak, Arch Pharmalabs had manufacturing facilities in Maharashtra and Goa, supplying APIs to formulation manufacturers in India and globally. However, Arch Pharmalabs encountered severe financial difficulties and was referred to the National Company Law Tribunal (NCLT) under the Insolvency and Bankruptcy Code (IBC) 2016. The company underwent insolvency resolution proceedings, marking a major setback for one of India's mid-tier API manufacturers. The insolvency proceedings attracted multiple resolution applicants interested in Arch's manufacturing assets, which retained value due to the company's established drug master files (DMFs) and API manufacturing capabilities. India's API sector is strategically critical — the country produces approximately 20% of global API supplies and is the world's largest supplier of generic APIs. The sector has received significant government attention post-COVID, with a PLI (Production Linked Incentive) scheme for bulk drugs announced in 2020 with Rs 6,940 crore outlay to reduce dependence on Chinese API imports. Arch Pharmalabs' manufacturing assets and intellectual property (drug master files, product registrations) represent valuable resources for the API sector. The company's case reflects the financial challenges faced by debt-laden mid-tier pharma manufacturers competing against both large Indian API companies and Chinese producers.

Key Milestones

Incorporated 1993 in Mumbai, Maharashtra (CIN: U24230MH1993PLC073741)

Common questions about unlisted shares

How do I buy Arch Pharmalabs unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

Arch Pharmalabs Limited

How settlement works

Get price alerts for Arch Pharmalabs Limited

Discuss Arch Pharmalabs

Similar companies

Other ways to invest